Please login to the form below
Lupin appoints Thierry Volle president for EMEA
He moves to the company from Vifor
Mumbai-based pharma company Lupin has appointed Thierry Volle to lead its Europe, Middle-East and Africa operations as president.
Volle will be responsible for the company's growth and development in Europe, Russia and CIS, as well as the Middle-East and African markets, and he will be based at Lupin's European headquarters in Zug, Switzerland.
He joins the firm from Vifor Pharma, where he was the head of EU and International business operations, and prior to that he served at Wyeth.
Vinita Gupta, Lupin's chief executive officer, said: "We are delighted to have Thierry join the Lupin family. His rich knowledge and experience in developing and growing businesses, specifically specialty pharmaceuticals in EMEA, will help us with our strategic expansion plans for these markets."
Featured jobs
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Scientific Director – Medical Communications
-
Salary TBC
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
-
Senior Medical Writer
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
-
Account Director, Medical Education
-
Salary TBC
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
- Senior Account Manager, Medical Communications, London
-
Excellent package
-
Health Consultant - Brand Comms
-
Competitive Salary
-
Digital Account Director
-
Salary TBC
Subscribe to our email news alerts
- Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
- Innovative approaches in the treatment of multiple sclerosis
- Undeterred by aducanumab failure, Eisai and Biogen plough on
- Mobilising the public to combat the antimicrobial resistance crisis
- Pharma fears “lack of focus” on no-deal Brexit preparations
- Supporting talent to LEAP to career heights…
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
- MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget....
- Innovative approaches in the treatment of multiple sclerosis
- Blue Latitude Health Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon....
- Mobilising the public to combat the antimicrobial resistance crisis
- Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. So why doesn’t the public seem bothered? BLH Account Executive Ford Stewart examines...
Quick links
Infographics
